Novel Mechanisms Beyond Anti-VEGF for Treatment of nAMD

Provider Statement: This continuing medical education activity is provided by .

Support Statement: This activity is supported by an educational grant from Allergan, Inc.

Target Audience: The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration.

Learning Objective:  Upon successful completion of this activity, participants should be better able to explore novel mechanisms of action of emerging therapies that may improve visual acuity and outcomes in patients with nAMD.

Activity Chair:
Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV

Faculty:
Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which is defined as answering ALL the posttest questions and includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, July 31, 2020, through July 30, 2021.

How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s):
Arshad M. Khanani, MD, MA
Consulting Fee: Adverum, Alcon, Allegro, Allergan, Bausch + Lomb, EyePoint, Gemini Therapeutics, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio
Speakers Bureau: Allergan, Novartis
Contracted Research: Adverum, Allegro, Allergan, Gemini Therapeutics, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, Regenxbio

Peter K. Kaiser, MD
Consulting Fee: Aerie, Aerpio, Alcon, Allegro, Allergan, Bausch + Lomb, Bayer, Biogen Idec, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Hospira, Irenix, jCyte, Kala, Kodiak, NGM Biopharmaceuticals, Novartis, Ocugenix, Omeros, Opthea, Oxurion (ThromboGenics), Regeneron, Regenxbio, Retinal Sciences, Roivant, Santen, SciFluor, Shire, Spark Therapeutics, Stealth Biotherapeutics, Verena (Digisight), Zeiss

Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at cme@vindicoCME.com